{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:21:27Z","timestamp":1719620487412},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"DOI":"10.7759\/cureus.63353","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:09:15Z","timestamp":1719569355000},"source":"Crossref","is-referenced-by-count":0,"title":["The Occurrence of Etoricoxib-Induced Stevens-Johnson Syndrome With Oral Manifestations in a Female Patient: A Case Study"],"prefix":"10.7759","author":[{"given":"Vasileios","family":"Zisis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Charisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Poulopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5530\/ijopp.14.1.13","article-title":"A case report on etoricoxib induced Stevens Johnson syndrome","volume":"14","author":"Kumar PS","year":"2021","unstructured":"Kumar PS, Tharuni B. A case report on etoricoxib induced Stevens Johnson syndrome. Indian J Pharm Pract. 2021, 14:10.5530\/ijopp.14.1.13","journal-title":"Indian J Pharm Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48728","article-title":"A compilation of drug etiologies of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"15","author":"Abulatan IT","year":"2023","unstructured":"Abulatan IT, Ben-David SG, Morales-Colon LA, Beason E, Fakoya AO. A compilation of drug etiologies of Stevens-Johnson syndrome and toxic epidermal necrolysis. Cureus. 2023, 15:e48728. 10.7759\/cureus.48728","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.153436","article-title":"A case report on toxic epidermal necrolysis with etoricoxib","volume":"47","author":"Kameshwari JS","year":"2015","unstructured":"Kameshwari JS, Devde R. A case report on toxic epidermal necrolysis with etoricoxib. Indian J Pharmacol. 2015, 47:221-3. 10.4103\/0253-7613.153436","journal-title":"Indian J Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko TM","year":"2011","unstructured":"Ko TM, Chung WH, Wei CY, et al.. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011, 128:1266-1276.e11. 10.1016\/j.jaci.2011.08.013","journal-title":"J Allergy Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft B","year":"2010","unstructured":"Kreft B, Wohlrab J, Bramsiepe I, Eismann R, Winkler M, Marsch WC. Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab. J Dermatol. 2010, 37:904-6. 10.1111\/j.1346-8138.2010.00893.x","journal-title":"J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12154","article-title":"Etoricoxib-induced toxic epidermal necrolysis","volume":"53","author":"Moutran R","year":"2014","unstructured":"Moutran R, Maatouk I, H\u00e9lou J. Etoricoxib-induced toxic epidermal necrolysis. Int J Dermatol. 2014, 53:e275-7. 10.1111\/ijd.12154","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_39_17","article-title":"Etoricoxib-induced toxic epidermal necrolysis: a fatal case report","volume":"50","author":"Roy SS","year":"2018","unstructured":"Roy SS, Mukherjee S, Era N, Mukherjee M. Etoricoxib-induced toxic epidermal necrolysis: a fatal case report. Indian J Pharmacol. 2018, 50:139-42. 10.4103\/ijp.IJP_39_17","journal-title":"Indian J Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau JC","year":"1997","unstructured":"Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997, 24:726-9. 10.1111\/j.1346-8138.1997.tb02524.x","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula P","year":"2013","unstructured":"Sekula P, Dunant A, Mockenhaupt M, et al.. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013, 133:1197-204. 10.1038\/jid.2012.510","journal-title":"J Invest Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/11593240-000000000-00000\/FIGURES\/TAB2","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann N","year":"2012","unstructured":"Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012, 13:49-54. 10.2165\/11593240-000000000-00000\/FIGURES\/TAB2","journal-title":"Am J Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan W","year":"2013","unstructured":"Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013, 149:1025-32. 10.1001\/jamadermatol.2013.4114","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.05.015","article-title":"Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis","volume":"135","author":"Wang Q","year":"2017","unstructured":"Wang Q, Sun S, Xie M, Zhao K, Li X, Zhao Z. Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis. Epilepsy Res. 2017, 135:19-28. 10.1016\/j.eplepsyres.2017.05.015","journal-title":"Epilepsy Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-118\/FIGURES\/2","article-title":"Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua R","year":"2011","unstructured":"Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011, 12:1-10. 10.1186\/1471-2350-12-118\/FIGURES\/2","journal-title":"BMC Med Genet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000306","article-title":"Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population","volume":"27","author":"Tempark T","year":"2017","unstructured":"Tempark T, Satapornpong P, Rerknimitr P, et al.. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017, 27:429-37. 10.1097\/FPC.0000000000000306","journal-title":"Pharmacogenet Genomics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki T","year":"2011","unstructured":"Ozeki T, Mushiroda T, Yowang A, et al.. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011, 20:1034-41. 10.1093\/hmg\/ddq537","journal-title":"Hum Mol Genet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi YW","year":"2017","unstructured":"Shi YW, Min FL, Zhou D, et al.. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology. 2017, 88:2183-91. 10.1212\/WNL.0000000000004008","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12058","article-title":"Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children","volume":"24","author":"Manuyakorn W","year":"2013","unstructured":"Manuyakorn W, Siripool K, Kamchaisatian W, et al.. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Pediatr Allergy Immunol. 2013, 24:299-303. 10.1111\/pai.12058","journal-title":"Pediatr Allergy Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko E","year":"2005","unstructured":"Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005, 94:419-36. 10.1016\/S1081-1206(10)61112-X","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269788-the-occurrence-of-etoricoxib-induced-stevens-johnson-syndrome-with-oral-manifestations-in-a-female-patient-a-case-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:09:18Z","timestamp":1719569358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269788-the-occurrence-of-etoricoxib-induced-stevens-johnson-syndrome-with-oral-manifestations-in-a-female-patient-a-case-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.63353","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}